Keyword Analysis & Research: imfinzi
Keyword Research: People who searched imfinzi also searched
Search Results related to imfinzi on Search Engine
-
Immunotherapy for BTC, uHCC, NSCLC & ES-SCLC – IMFINZI® …
https://www.imfinzi.com/
WEBIMFINZI® (durvalumab) is an immunotherapy approved to treat patients with unresectable hepatocellular carcinoma, bile duct cancer, gallbladder cancer, unresectable Stage 3 NSCLC, Stage 4 NSCLC, and extensive-stage SCLC.
DA: 63 PA: 95 MOZ Rank: 5
-
Imfinzi: Uses, Dosage, Side Effects & Warnings - Drugs.com
https://www.drugs.com/imfinzi.html
WEBJun 2, 2023 · Imfinzi (durvalumab) is a cancer medicine that works with your immune system to interfere with the growth and spread of cancer cells in the body. Imfinzi is used to treat non-small cell lung cancer (NSCLC), small cell lung cancer, or biliary tract cancer.
DA: 9 PA: 37 MOZ Rank: 37
-
Imfinzi: Side Effects, Use for Lung Cancer, Dosage, and More
https://www.healthline.com/health/drugs/imfinzi
WEBAug 23, 2022 · What is Imfinzi? If you’ve been diagnosed with lung cancer, your doctor may suggest treatment with Imfinzi. Imfinzi is prescribed to treat the following types of lung cancer in adults: small...
DA: 16 PA: 88 MOZ Rank: 57
-
Durvalumab - Wikipedia
https://en.wikipedia.org/wiki/Durvalumab
WEBDurvalumab, sold under the brand name Imfinzi, is an FDA-approved immunotherapy for cancer, developed by Medimmune/AstraZeneca. It is a human immunoglobulin G1 kappa (IgG1κ) monoclonal antibody that blocks the interaction of programmed cell death ligand 1 ( PD-L1 ) with the PD-1 (CD279).
DA: 53 PA: 85 MOZ Rank: 58
-
Imfinzi (durvalumab): Side effects, dosage, uses, and more
https://www.medicalnewstoday.com/articles/imfinzi
WEBFeb 7, 2024 · Imfinzi is a brand-name drug that’s prescribed for certain cancers, including some types of lung cancer. Imfinzi contains the active ingredient durvalumab. It’s given as an intravenous (IV)...
DA: 39 PA: 25 MOZ Rank: 49
-
What Is IMFINZI® (durvalumab)?
https://www.imfinzi.com/stage-3-lung-cancer/imfinzi-lung-cancer-treatment
WEBIMFINZI ® (durvalumab) is a prescription medicine used to treat a type of lung cancer called non-small cell lung cancer (NSCLC). IMFINZI may be used when your NSCLC has not spread outside your chest, cannot be removed by surgery, and has responded or stabilized with initial treatment with chemotherapy that contains platinum, given at the same ...
DA: 67 PA: 4 MOZ Rank: 74
-
What is IMFINZI® (durvalumab) – Treatment for ES-SCLC
https://www.imfinzi.com/small-cell-lung-cancer/about/what-is-imfinzi.html
WEBIMFINZI IS AN IMMUNOTHERAPY TREATMENT. IMFINZI ® (durvalumab) is a prescription medicine that works with the immune system to help the body fight cancer. It is used to treat extensive-stage small cell lung cancer (ES-SCLC) in combination with chemotherapy. IMFINZI may also attack healthy cells.
DA: 75 PA: 70 MOZ Rank: 42
-
IMFINZI® - AstraZeneca US
https://medicalinformation.astrazeneca-us.com/home/prescribing-information/imfinzi.html
WEBSerious adverse reactions occurred in 47% of patients receiving IMFINZI plus chemotherapy. The most frequent serious adverse reactions reported in at least 2% of patients were cholangitis (7%), pyrexia (3.8%), anemia (3.6%), sepsis (3.3%) and acute kidney injury (2.4%).
DA: 31 PA: 64 MOZ Rank: 46
-
Durvalumab (Imfinzi) | FDA
https://www.fda.gov/drugs/resources-information-approved-drugs/durvalumab-imfinzi
WEBOn May 1, 2017, the U.S. Food and Drug Administration granted accelerated approval to durvalumab (IMFINZI, AstraZeneca UK Limited) for the treatment of patients with locally advanced or...
DA: 44 PA: 80 MOZ Rank: 18
-
IMFINZI® (durvalumab) plus chemotherapy approved in the US …
https://www.astrazeneca-us.com/media/press-releases/2022/imfinzi-durvalumab-plus-chemotherapy-approved-in-the-us-as-the-first-immunotherapy-regimen-for-patients-with-advanced-biliary-tract-cancer-09052022.html
WEBSep 5, 2022 · IMFINZI® (durvalumab) plus chemotherapy approved in the US as the first immunotherapy regimen for patients with advanced biliary tract cancer. PUBLISHED 5 September 2022. Approval based on TOPAZ-1 Phase III trial results, which showed IMFINZI combination reduced risk of death by 20% vs. chemotherapy alone.
DA: 2 PA: 91 MOZ Rank: 91